Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471–86.

Article  CAS  PubMed  Google Scholar 

Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27

Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics. 2011;5:156–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arenz C. Recent advances and novel treatments for sphingolipidoses. Future Med Chem. 2017;9:1685–98.

Article  CAS  Google Scholar 

Fecarotta S, Tarallo A, Damiano C, Minopoli N, Parenti G. Pathogenesis of mucopolysaccharidoses, an update. Int J Mol Sci. 2020;21:1–14.

Article  Google Scholar 

Khan SA, Tomatsu SC. Mucolipidoses overview: past, present, and future. Int J Mol Sci. 2020;21:1–20.

Article  Google Scholar 

Ellingwood SS, Cheng A. Biochemical and clinical aspects of glycogen storage diseases. J Endocrinol. 2018;238:R131–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parenti G, Medina DL, Ballabio A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol Med. 2021;13:1–21.

Article  Google Scholar 

Kingma SDK, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015;29:145–57.

Article  PubMed  Google Scholar 

Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, et al. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan. Mol Genet Metab. 2021;133:277–88.

Article  CAS  PubMed  Google Scholar 

The portal for rare diseases and orphan drugs. Orpha.net https://www.orpha.net/consor/cgi-bin/Disease.php?lng=EN. Accessed 16 Apr 2024.

Oder D, Nordbeck P, Wanner C. Long term treatment with enzyme replacement therapy in patients with Fabry disease. Nephron. 2016;134:30–6.

Article  CAS  PubMed  Google Scholar 

Dinur T, Grittner U, Revel-Vilk S, Becker-Cohen M, Istaiti M, Cozma C, et al. Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations. Int J Mol Sci. 2021;22:1–11.

Article  Google Scholar 

Fernández-Pereira C, Millán-Tejado BS, Gallardo-Gómez M, Pérez-Márquez T, Alves-Villar M, Melcón-Crespo C, et al. Therapeutic approaches in lysosomal storage diseases. Biomolecules. 2021;11:1–19.

Article  Google Scholar 

Sly WS, Vogler C, Grubb JH, Levy B, Galvin N, Tan Y, et al. Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci USA. 2006;103:15172–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen JC, Luu AR, Wise N, de Angelis R, Agrawal V, Mangini L, et al. Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice. J Biol Chem. 2020;295:13532–55.

Article  CAS  PubMed  Google Scholar 

Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE. 2012;7:1–7.

Article  Google Scholar 

Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017;118:109–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ortolano S. Small molecules: substrate inhibitors, chaperones, stop-codon read through, and beyond. J Inborn Errors Metab Screen. 2016;4:1–11.

Article  CAS  Google Scholar 

Jung O, Patnaik S, Marugan J, Sidransky E, Westbroek W. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its potential implications for Parkinson disease. Expert Rev Proteomics. 2017;13:471–9.

Article  Google Scholar 

Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54:288–96.

Article  CAS  PubMed  Google Scholar 

Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23:1138–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J. 1996;13:153–7.

Article  CAS  PubMed  Google Scholar 

Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics. 2021;15:353–61.

Redhwan MAM, Hariprasad MG, Samaddar S, Hard SAAA, Yadav V, Mukherjee A, et al. Small interference (RNAi) technique: exploring its clinical applications, benefits and limitations. Eur J Clin Invest. 2023;53:1–14.

Article  Google Scholar 

Chris BM, Elizabeth HG, Huang MT-H, Debra JT. Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol. 2010;29:393–5.

Google Scholar 

Svoboda P. Key mechanistic principles and considerations concerning RNA interference. Front Plant Sci. 2020;11:1–13.

Article  Google Scholar 

Naghizadeh S, Mansoori B, Mohammadi A, Sakhinia E, Baradaran B. Gene silencing strategies in cancer therapy: an update for drug resistance. Curr Med Chem. 2018;26:6282–303.

Article  Google Scholar 

Onpattro | Highlights of prescribing information. Dailymed.nlm.nih.gov https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970. Accessed 16 Apr 2024.

Givlaari | European Medicines Agency. Ema.europa.ue/en. https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari. Accessed 16 Apr 2024.

Oxlumo | European Medicines Agency. Ema.europa.ue/en. https://www.ema.europa.eu/en/medicines/human/EPAR/oxlumo. Accessed 16 Apr 2024.

Leqvio | European Medicines Agency. Ema.europa.ue/en. https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio. Accessed 16 Apr 2024.

Amvuttra | European Medicines Agency. Ema.europa.ue/en. https://www.ema.europa.eu/en/medicines/human/EPAR/famvuttra. Accessed 16 Apr 2024.

Rivfloza | Highlights of prescribing information. Dailymed.nlm.nih.gov https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ace9d4bc-4d20-4beb-9e9d-888690424833. Accessed 16 Apr 2024.

Crooke ST, Liang XH, Baker BF, Crooke RM. Antisense technology: a review. J Biol Chem. 2021;296: 100416.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gheibi-Hayat SM, Jamialahmadi K. Antisense oligonucleotide (AS-ODN) technology: principle, mechanism and challenges. Biotechnol Appl Biochem. 2021;68:1086–94.

Article  CAS  PubMed  Google Scholar 

Xiong H, Veedu RN, Diermeier SD. Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sci. 2021;22:3295.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rein LAM, Yang H, Chao NJ. Applications of gene editing technologies to cellular therapies. Biol Blood Marrow Transplant. 2018;24:1537–45.

Article  CAS  PubMed  Google Scholar 

Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang F, Qin Z, Lu H, He S, Luo J, Jin C, et al. Clinical translation of gene medicine. J Gene Med. 2019;21:1–8.

Article  Google Scholar 

del Pozo-Rodríguez A, Rodríguez-Gascón A, Rodríguez-Castejón J, Vicente-Pascual M, Gómez-Aguado I, Battaglia LS, et al. Gene therapy. Adv Biochem Eng Biotechnol. 2019;123:127–41.

Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.